Skip to content
value.today

Reset Therapeutics, Inc.

Formerly Sircadian, Inc.

Total raised
$54 M
5 rounds on record
Latest round
$2 M
Jan 2022
First round on record
Nov 2013
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Reset Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2022$2 MNo. 5Under $2 million

Reset Therapeutics, Inc.: Raise no. 5, Jan 2022

Investors in this round

3 investors had bought by the notice of Jan 25, 2022: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Glenn B Batchelder · Executive Officer, Director
  • Shu B Kurosaki · Executive Officer
  • Blair B Jackson · Director
  • Frederick B Craves · Director
  • Steve B Kay · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shu Kurosaki, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 25, 2022. Read the notice at the SEC.

debt, optionsSEC
Sep 2019$6 MNo. 4$2 to $10 million

Reset Therapeutics, Inc.: Raise no. 4, Sep 2019

Investors in this round

3 investors had bought by the notice of Oct 24, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Glenn B Batchelder · Executive Officer, Director
  • Shuichi B Kurosaki · Executive Officer
  • Blair B Jackson · Director
  • Frederick B Craves · Director
  • Steve B Kay · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shuichi Kurosaki, Treasurer. Source: SEC Form D, newest notice filed Oct 24, 2019. Read the notice at the SEC.

debt, optionsSEC
Jun 2018$2 MNo. 3Under $2 million

Reset Therapeutics, Inc.: Raise no. 3, Jun 2018

Investors in this round

3 investors had bought by the notice of Jun 20, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shuichi B Kurosaki · Executive Officer
  • Blair B Jackson · Director
  • Frederick B Craves · Director
  • Glenn B Batchelder · Director
  • Steve B Kay · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shuichi Kurosaki, Treasurer. Source: SEC Form D, newest notice filed Jun 20, 2018. Read the notice at the SEC.

debt, optionsSEC
Feb 2016$30 MNo. 2$10 to $50 million

Reset Therapeutics, Inc.: Raise no. 2, Feb 2016

Investors in this round

2 investors had bought by the notice of Feb 19, 2016: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $47 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul B Humphries · Executive Officer
  • Ross Bersot · Executive Officer, Director
  • Shuichi B Kurosaki · Executive Officer
  • Frederick B Craves · Director
  • Hoyoung B Huh · Director
  • Peter B Schultz · Director
  • Steve B Kay · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shuichi Kurosaki, Treasurer. Source: SEC Form D, newest notice filed Feb 19, 2016. Read the notice at the SEC.

equitySEC
Nov 2013$15 MNo. 1$10 to $50 million

Reset Therapeutics, Inc.: Raise no. 1, Nov 2013

Investors in this round

2 investors had bought by the notice of Dec 3, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $16 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul B Humphries · Executive Officer
  • Ross Bersot · Executive Officer, Director
  • Shuichi B Kurosaki · Executive Officer
  • Frederick B Craves · Director
  • Peter B Schultz · Director
  • Steve B Kay · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ross Bersot, President. Source: SEC Form D, newest notice filed Dec 3, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Reset Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2022).

    SEC Form D · Jan 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2022

That is all the official record says: Reset Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Reset Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 3 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Reset Therapeutics, Inc.
NameRoleNamed in
Glenn B BatchelderExecutive officerJan 2022
Shu B KurosakiExecutive officerJan 2022
Shuichi B KurosakiExecutive officerOct 2019
Paul B HumphriesExecutive officerFeb 2016
Ross BersotExecutive officerFeb 2016
Blair B JacksonDirectorJan 2022
Frederick B CravesDirectorJan 2022
Glenn B BatchelderDirectorJan 2022
Steve B KayDirectorJan 2022
Hoyoung B HuhDirectorFeb 2016
Peter B SchultzDirectorFeb 2016
Ross BersotDirectorFeb 2016